MADRIGAL PHARMACEUTICALS
Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including diabetes, dyslipidemia and cardiovascular disease.
MADRIGAL PHARMACEUTICALS
Industry:
Biotechnology Medical Device Pharmaceutical
Founded:
2011-01-01
Address:
Washington, Pennsylvania, United States
Country:
United States
Website Url:
http://www.madrigalpharma.com
Total Employee:
1+
Status:
Active
Contact:
(267) 327-4445
Email Addresses:
[email protected]
Total Funding:
288.38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager WordPress Domain Not Resolving Wordpress Plugins Nginx IPv6
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Madrigal Pharmaceuticals
Bay City Capital
Bay City Capital investment in Post-IPO Equity - Madrigal Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-10 | Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer |
Official Site Inspections
http://www.madrigalpharma.com Semrush global rank: 2.78 M Semrush visits lastest month: 5.83 K
- Host name: 104.18.22.189
- IP address: 104.18.22.189
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Madrigal Pharmaceuticals"
Madrigal Pharmaceuticals โ Transforming the Treatment of Non โฆ
Nov 6, 2024ย ยท Madrigal is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated โฆSee details»
Leadership โ Madrigal Pharmaceuticals
Madrigalโs leadership team is comprised of individuals with proven track records developing multiple FDA-approved medicines and expertise in building and leading successful โฆSee details»
Madrigal Pharmaceuticals - LinkedIn
Madrigal (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH).See details»
Madrigal Pharmaceuticals - Crunchbase Company โฆ
Madrigal Pharmaceuticals is a biopharmaceutical company developing therapeutics for the treatment of cardiovascular-metabolic diseases. Madrigal Pharmaceuticals received FDA approval for its NASH drug, Rezdiffra, and โฆSee details»
Madrigal Pharmaceuticals Announces Support of Fatty Liver
Oct 4, 2021ย ยท Madrigal is providing an unrestricted grant to support FLFโs NAFLD Screening Fund whose primary objective is to scale-up evidence-based screening and testing for NAFLD in a โฆSee details»
About Us - Madrigal Pharmaceuticals
Madrigal is a biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis โฆSee details»
Annual Reports | Madrigal Pharmaceuticals.
Madrigalโs ambitious research programs led to the first FDA-approved treatment in NASH.See details»
Madrigal Pharmaceuticals Provides Corporate Updates and โฆ
Nov 6, 2023ย ยท Our New Drug Application is supported by the largest and most advanced development program in NASH and our commercial strategy is grounded in resmetiromโs โฆSee details»
ETHICS and COMPLIANCE โ Madrigal Pharmaceuticals
Madrigal is committed to fostering an open dialogue at all levels of the organization regarding ethics and compliance matters. Madrigal personnel are encouraged consult with the โฆSee details»
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive ...
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high โฆSee details»
Madrigal Pharmaceuticals - Craft
Oct 29, 2024ย ยท See insights on Madrigal Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Madrigal Pharmaceuticals Provides Business and Clinical Updates โฆ
CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics โฆSee details»
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief โฆ
CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics โฆSee details»
Board Of Directors โ Madrigal Pharmaceuticals
Craves co-founded and served as Chairman of the Board of Private Madrigal, a privately-held biopharmaceutical company, from its inception in September 2011 through the Merger โฆSee details»
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra ...
CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for โฆSee details»
Careers โ Madrigal Pharmaceuticals
Join our growing team focused on transforming the treatment of people with liver diseases. Madrigal is an Equal Opportunity Employer. All employment is decided on the basis of โฆSee details»
Corporate Presentations | Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals. 200 Barr Harbor Drive, Suite 200. West Conshohocken, Pennsylvania 19428See details»
Our Programs โ Madrigal Pharmaceuticals
Madrigal is the leading biopharmaceutical company studying the therapeutic potential of THR-ฮฒ agonism to improve liver health for patients with NASH.See details»
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial โฆ
CONSHOHOCKEN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for โฆSee details»